Race

Visit number vs Tumor necrosis factor-alpha receptor-1
N Mean StdDev Median Min Max Unknown Total
Baseline 317 1,589.6 ± 575.6 1,442.7 80.1 4,258.9 1 318
Follow-up 295 1,638.7 ± 623.2 1,448.5 734.7 4,510.6 6 301
Treatment Arm vs Tumor necrosis factor-alpha receptor-1
Baseline
N Mean StdDev Median Min Max Unknown Total
Total 317 1,589.6 ± 575.6 1,442.7 80.1 4,258.9 1 318
Healthy Lifestyles and Sleep Education - control arm (HLSE) 106 1,639.5 ± 626.0 1,496.6 733.1 3,899.7 - 106
Healthy Lifestyles and Sleep Education + (supplemental nocturnal) Oxygen - oxygen arm (HLSE-O) 105 1,612.0 ± 602.7 1,459.7 80.1 4,258.9 1 106
Healthy Lifestyles and Sleep Education + Positive airway pressure treatment - CPAP arm (HLSE-P) 106 1,517.6 ± 487.1 1,416.4 381.0 3,126.1 - 106
Treatment Arm vs Tumor necrosis factor-alpha receptor-1
Follow-up
N Mean StdDev Median Min Max Unknown Total
Total 295 1,638.7 ± 623.2 1,448.5 734.7 4,510.6 6 301
Healthy Lifestyles and Sleep Education - control arm (HLSE) 99 1,719.9 ± 722.9 1,527.3 855.6 4,510.6 1 100
Healthy Lifestyles and Sleep Education + (supplemental nocturnal) Oxygen - oxygen arm (HLSE-O) 98 1,617.7 ± 562.4 1,462.6 857.6 3,833.3 3 101
Healthy Lifestyles and Sleep Education + Positive airway pressure treatment - CPAP arm (HLSE-P) 98 1,577.8 ± 567.6 1,408.4 734.7 3,949.1 2 100
Age category vs Tumor necrosis factor-alpha receptor-1
Baseline
N Mean StdDev Median Min Max Unknown Total
Total 317 1,589.6 ± 575.6 1,442.7 80.1 4,258.9 1 318
45-54 years 53 1,461.3 ± 587.2 1,356.8 80.1 3,899.7 - 53
55-64 years 139 1,524.4 ± 543.2 1,418.7 381.0 3,858.3 - 139
65 years or older 125 1,716.7 ± 586.0 1,595.5 824.8 4,258.9 1 126
Age category vs Tumor necrosis factor-alpha receptor-1
Follow-up
N Mean StdDev Median Min Max Unknown Total
Total 295 1,638.7 ± 623.2 1,448.5 734.7 4,510.6 5 300
45-54 years 46 1,526.9 ± 549.6 1,356.7 938.7 4,124.8 3 49
55-64 years 125 1,536.8 ± 571.4 1,375.7 842.1 4,040.1 2 127
65 years or older 124 1,783.0 ± 672.8 1,618.8 734.7 4,510.6 - 124
Gender of the participant vs Tumor necrosis factor-alpha receptor-1
Baseline
N Mean StdDev Median Min Max Unknown Total
Total 317 1,589.6 ± 575.6 1,442.7 80.1 4,258.9 1 318
Female 83 1,659.9 ± 681.3 1,492.5 80.1 4,258.9 1 84
Male 234 1,564.7 ± 532.6 1,426.1 733.1 3,899.7 - 234
Gender of the participant vs Tumor necrosis factor-alpha receptor-1
Follow-up
N Mean StdDev Median Min Max Unknown Total
Total 295 1,638.7 ± 623.2 1,448.5 734.7 4,510.6 6 301
Female 78 1,735.0 ± 722.7 1,456.2 842.1 4,040.1 1 79
Male 217 1,604.1 ± 581.3 1,447.2 734.7 4,510.6 5 222
Race of the participant vs Tumor necrosis factor-alpha receptor-1
Baseline
N Mean StdDev Median Min Max Unknown Total
Total 316 1,586.5 ± 573.8 1,442.1 80.1 4,258.9 1 317
White 256 1,563.4 ± 516.5 1,448.3 80.1 3,899.7 - 256
American Indian or Alaskan Native 2 1,633.1 ± 735.1 1,633.1 1,113.3 2,152.8 - 2
Black or African American 42 1,740.4 ± 847.6 1,397.1 716.3 4,258.9 1 43
Asian 6 1,354.4 ± 219.5 1,392.9 986.6 1,601.3 - 6
Native Hawaiian or other Pacific islander 1 1,898.2 - 1,898.2 1,898.2 1,898.2 - 1
Other 4 1,812.2 ± 872.5 1,641.8 952.2 3,012.8 - 4
Multiple 5 1,490.5 ± 582.7 1,356.8 1,011.5 2,484.2 - 5
Race of the participant vs Tumor necrosis factor-alpha receptor-1
Follow-up
N Mean StdDev Median Min Max Unknown Total
Total 294 1,633.9 ± 618.8 1,447.9 734.7 4,510.6 5 299
White 238 1,617.2 ± 561.7 1,480.0 734.7 4,510.6 3 241
American Indian or Alaskan Native 2 1,670.8 ± 424.4 1,670.8 1,370.8 1,970.9 - 2
Black or African American 39 1,767.4 ± 900.7 1,346.0 842.1 4,040.1 2 41
Asian 6 1,339.3 ± 215.9 1,362.9 1,006.1 1,593.9 - 6
Native Hawaiian or other Pacific islander 1 1,965.4 - 1,965.4 1,965.4 1,965.4 - 1
Other 3 2,056.3 ± 1,058.8 1,616.3 1,288.4 3,264.2 - 3
Multiple 5 1,406.7 ± 663.2 1,351.9 858.8 2,520.5 - 5